doi:10.19983/j.issn.2096-8493.20260141

Abstract

CLC Number:

Figures/Tables 4

References 18

[1]	World Health Organization. Global tuberculosis report 2025[R]. Geneva: World Health Organization, 2025.
[2]	Solans B P, Imperial M Z, Olugbosi M, et al. Analysis of Dynamic Efficacy Endpoints of the Nix-TB Trial[J]. Clin Infect Dis, 2023, 76(11):1903-1910. doi:10.1093/cid/ciad051. pmid: 36804834
[3]	Saluzzo F, Adepoju V A, Duarte R, et al. Treatment-shortening regimens for tuberculosis: updates and future priorities[J]. Breathe (Sheff), 2023, 19(3):230028. doi:10.1183/20734735.0028-2023.
[4]	Esmail A, Oelofse S, Lombard C, et al. An All-Oral 6-Month Regimen for Multidrug-Resistant Tuberculosis: A Multicenter, Randomized Controlled Clinical Trial (the NExT Study)[J]. Am J Respir Crit Care Med, 2022, 205(10):1214-1227. doi:10.1164/rccm.202107-1779OC.
[5]	World Health Organization. WHO consolidated guidelines on tuberculosis: Module 4: treatment-drug-resistant tuberculosis treatment, 2022 update[R]. Geneva: World Health Organization, 2022.
[6]	李颍, 杜鹃, 魏双. 结核病短程治疗的研究现状和思考[J]. 内科急危重症杂志, 2025, 31(5):422-428. doi:10.11768/nkjwzzzz20250506.
[7]	Davoli C, Rossi C, Ciccarone A, et al. Can 6-month long regimens become the standardized treatment for MDR-TB globally?[J]. Int J Infect Dis, 2025, 160:108065. doi:10.1016/j.ijid.2025.108065.
[8]	初乃惠. 以时不我待的精神探索中国耐药肺结核患者全口服化学治疗方案[J]. 中国防痨杂志, 2021, 43(9):857-858. doi:10.3969/j.issn.1000-6621.2021.09.001.
[9]	中华医学会结核病学分会. 中国耐多药/利福平耐药结核病化学治疗指南(2026年版)[J]. 中华结核和呼吸杂志, 2026, 49(6):623-643. doi:10.3760/cma.j.cn112147-20251104-00674.
[10]	Nyang’wa B T, Berry C, Kazounis E, et al. Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial[J]. Lancet Respir Med, 2024, 12(2):117-128. doi:10.1016/S2213-2600(23)00389-2.
[11]	Ndjeka N, Perumal R, Romanowski K, et al. Treatment outcomes and drug-related adverse events across four short-course RR-TB regimens in South Africa: A retrospective analysis[J]. Int J Infect Dis, 2026, 165:108473. doi:10.1016/j.ijid.2026.108473.
[12]	Sangsayunh P, Sanchat T, Chuchottaworn C, et al. The use of BPaL containing regimen in the MDR/PreXDR TB treatments in Thailand[J]. J Clin Tuberc Other Mycobact Dis, 2023, 34:100408. doi:10.1016/j.jctube.2023.100408.
[13]	许岩, 路希维, 蔡春葵, 等. 治疗失败耐多药肺结核患者CT征象演变的回顾性分析[J]. 中国防痨杂志, 2020, 42(6):549-557. doi:10.3969/j.issn.1000-6621.2020.06.004.
[14]	秦李祎, 吕岩, 杨阳, 等. 肺结核患者治愈后肺内残留的非活动性结核病灶的CT特征研究[J]. 中国防痨杂志, 2022, 44(4):336-342. doi:10.19982/j.issn.1000-6621.20210734.
[15]	王利萍. 肺结核患者耐多药结核病的危险因素分析[J]. 系统医学, 2024, 9(19):78-80. doi:10.19368/j.cnki.2096-1782.2024.19.078.
[16]	罗季, 陈永刚, 马雅妮, 等. 儿童耐多药结核病发生的相关影响因素及其预测模型的建立[J]. 安徽医药, 2024, 28(3):592-596. doi:10.3969/j.issn.1009-6469.2024.03.037.
[17]	杜彩云, 阿尔泰, 李媛媛, 等. 877例耐药肺结核患者流行病学情况及相关因素分析[J]. 临床肺科杂志, 2024, 29(6):907-914. doi:10.3969/j.issn.1009-6663.2024.06.018.
[18]	Giovenco D, Shah N S, Ansorge K, et al. New drugs are not enough: addressing social determinants as a critical component of drug-resistant TB care[J]. IJTLD Open, 2025, 2(4):183-186. doi:10.5588/ijtldopen.25.0075. pmid: 40226138

项目	2025-04-08	2025-05-08	2025-06-11	2025-07-16	2025-08-12	2025-09-01	2025-10-10
痰涂片镜检	阳性	阳性	阴性	阳性	阴性	阴性	阴性
分枝杆菌培养	阳性	阳性	阴性	阴性	阴性	阴性	阴性

项目	2025-04-14	2025-05-29	2025-06-18	2025-07-16	2025-08-27	2025-09-26	2025-10-21
痰涂片镜检	阳性	阴性	阴性	阴性	阴性	阴性	阴性
分枝杆菌培养	阳性	阴性	阴性	阴性	阴性	阴性	阴性

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 4

References 18

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Ma Zhiming. Interpretation of Chinese Expert Consensus on Diagnosis and Treatment of Pneumoconiosis Complicated with Pulmonary Tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2026, 7(5): 559-563.
[2]	Nie Ligang, Zhang Mingyue, Amina·Mamuti , Wang Xueyu, Lu Shuihua, Nie Wenjuan. Study design of a single-arm feasibility trial of the ultra-short-course B-P-L-S-Z regimen for rifampicin-resistant tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2026, 7(5): 568-573.
[3]	Zeng Chunmei, Lu Qingxia, Nie Wenjuan, Zhu Qingdong, Chu Naihui, Zhu Fengmei. A phase Ⅱ clinical study on the early bactericidal activity, safety, and tolerability of oral sudapyridine (WX-081) tablets in patients with newly diagnosed drug-susceptible and drug-resistant pulmonary tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2026, 7(5): 574-580.
[4]	Yi Benju, Tang Yuhong, Mo Yixin, Jiang Lina, Liao Yi. Analysis of tuberculosis infection and associated factors among household close contacts of active pulmonary tuberculosis patients in Hechuan District, Chongqing City [J]. Journal of Tuberculosis and Lung Disease, 2026, 7(5): 581-588.
[5]	Pang Yan, Wu Chengguo, Wang Qingya, Peng Peng. Analysis of the factors influencing medication adherence among pulmonary tuberculosis patients in Chongqing City from 2021 to 2024 [J]. Journal of Tuberculosis and Lung Disease, 2026, 7(5): 589-595.
[6]	Li Yingying, Ren Yan. Research progress on adrenal insufficiency associated with adrenal tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2026, 7(5): 665-672.
[7]	Pan Lihua, Zhan Lu. Clinical value and research progress of urinary lipoarabinomannan detection in the diagnosis of pediatric tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2026, 7(5): 673-678.
[8]	Jiang Ping, Li Tianju, Kang Guanghong, Xiang Mingque. Research progress on prevention and control strategies for latent Mycobacterium tuberculosis infection [J]. Journal of Tuberculosis and Lung Disease, 2026, 7(5): 679-686.
[9]	Zhang Yuhao, Wang Dan, Wang Shuhan, Li Chen, Zheng Chanjuan, Tang Wenjie, Yang Yide, Gong Fanghua. Mobile health technology for improving treatment adherence in tuberculosis patients: a review [J]. Journal of Tuberculosis and Lung Disease, 2026, 7(5): 687-693.
[10]	. [J]. Journal of Tuberculosis and Lung Disease, 2026, 7(5): 731-732.
[11]	. [J]. Journal of Tuberculosis and Lung Disease, 2026, 7(4): 539-540.
[12]	. [J]. Journal of Tuberculosis and Lung Disease, 2026, 7(4): 534-538.
[13]	Yuan Jingsong, Lin Yi, Deng Guofang, Chen Jingfang, Meng Ting, Wu Yuanling. Research progress on caregiver burden and intervention strategies for patients with tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2026, 7(4): 520-525.
[14]	Yang Yan, Chen Siying, Yang Xuejuan, Na Hong, Deng Fumei, Wang Haiyan. Visualization analysis of tuberculosis nutrition research based on CiteSpace [J]. Journal of Tuberculosis and Lung Disease, 2026, 7(4): 493-501.
[15]	Zhang Yaxi, Yu Hong, Li Jing, Gou Jizhou, Yang Qianting, Zhan Senlin, Chen Qi. Diagnostic value of combining HE staining with three pathogen detection methods in tuberculosis histopathology for improving the positivity rate of active tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2026, 7(4): 487-492.